
FOMX
Other · Other · $183.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2019
EPS trend, 90 days to now · +29.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 1, 2019 | Time not confirmed | -0.24 | -0.26 | -7.9% |
| Nov 8, 2018 | Time not confirmed | -0.47 | -0.38 | +19.4% |
| Aug 9, 2018 | Time not confirmed | -0.56 | -0.46 | +17.1% |
| May 9, 2018 | Time not confirmed | -0.45 | -0.69 | -53.8% |
| Feb 28, 2018 | Time not confirmed | -0.41 | -0.46 | -12.9% |
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of…